CANF vs PFE

Can-Fite BioPharma Ltd. remains an extremely high-risk, deeply speculative investment, with a very low probability of achieving 10x growth within 3-5 years. While FY2025 financials show declining revenue and worsening net loss, recent material positive catalysts warrant a slight score increase. These include an improved short-term cash position (+$4.3M in March 2026, totaling ~$12.84M), significan...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...